Payment overview · 2025
General Payments
$280.82
14 reported records · 10 companies
Healthcare provider profile · identity verified
Julius S Vonclef, MD
Allopathic & Osteopathic Physicians|Family Medicine · POWELL, TN · NPI 1740226646
Verified facts
What the public records show
CMS Open Payments records show Julius S Vonclef, MD received $280.82 in general payments during 2025 across 14 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Kerendia, Ozempic, Rexulti, Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.25 | 22.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.28 | 21.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.43 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.18 | 10.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.02 | 7.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.08 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.62 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.21 | 5.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.12 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.82 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.25 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 146 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
146 | 146 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 407 | 95 |
| Omeprazole | Omeprazole | 306 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 56 |
| Gabapentin | Gabapentin | 229 | 49 |
| Spironolactone | Spironolactone | 229 | 49 |
| Potassium Chloride | Potassium Chloride | 205 | 49 |
| Clonazepam | Clonazepam | 204 | 29 |
| Metformin Hcl Er | Metformin Hcl | 184 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 179 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 30 |
| Famotidine | Famotidine | 147 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 146 | 146 |
| Jardiance | Empagliflozin | 146 | 33 |
| Irbesartan | Irbesartan | 145 | 27 |
| Furosemide | Furosemide | 130 | 34 |
| Alprazolam | Alprazolam | 129 | 21 |
| Trazodone Hcl | Trazodone Hcl | 128 | 31 |
| Montelukast Sodium | Montelukast Sodium | 125 | 29 |
| Lisinopril | Lisinopril | 122 | 30 |
| Ezetimibe | Ezetimibe | 118 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 115 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 27 |
| Benazepril Hcl | Benazepril Hcl | 107 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 23 |
| Buspirone Hcl | Buspirone Hcl | 106 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | suppressed |
| Methocarbamol | Methocarbamol | 101 | 14 |
| Eliquis | Apixaban | 98 | 17 |
| Losartan Potassium | Losartan Potassium | 98 | 28 |
| Synthroid | Levothyroxine Sodium | 92 | 15 |
| Azithromycin | Azithromycin | 87 | 68 |
| Bupropion Xl | Bupropion Hcl | 87 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 17 |
| Mounjaro | Tirzepatide | 83 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 31 |
| Celecoxib | Celecoxib | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 21 |
| Donepezil Hcl | Donepezil Hcl | 78 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 18 |
| Promethazine Hcl | Promethazine Hcl | 77 | 13 |
| Lorazepam | Lorazepam | 76 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 17 |
| Atenolol | Atenolol | 73 | 12 |
| Estradiol | Estradiol | 71 | 16 |
| Memantine Hcl | Memantine Hcl | 71 | suppressed |
| Carvedilol | Carvedilol | 70 | 15 |
| Meloxicam | Meloxicam | 70 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 17 |
| Meclizine Hcl | Meclizine Hcl | 69 | 14 |
| Ondansetron Odt | Ondansetron | 69 | 12 |
| Pregabalin | Pregabalin | 68 | 16 |
| Tramadol Hcl | Tramadol Hcl | 68 | 16 |
| Vascepa | Icosapent Ethyl | 66 | 15 |
| Glipizide | Glipizide | 65 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 61 | 17 |
| Chlorthalidone | Chlorthalidone | 58 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | suppressed |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | suppressed |
| Simvastatin | Simvastatin | 56 | 16 |
| Fluconazole | Fluconazole | 55 | 27 |
| Prednisone | Prednisone | 54 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Acyclovir | Acyclovir | 50 | 16 |
| Levofloxacin | Levofloxacin | 48 | 37 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 11 |
| Baclofen | Baclofen | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 29 |
| Armour Thyroid | Thyroid,pork | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Valsartan | Valsartan | 38 | 11 |
| Glimepiride | Glimepiride | 37 | 11 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 21 |
| Rabeprazole Sodium | Rabeprazole Sodium | 31 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Indapamide | Indapamide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 25 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 15 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.82 · 14 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, CAPLYTA, FARXIGA, JARDIANCE, Kerendia, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error